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Summary The outcome of cancer chemotherapy is determined by an interplay of multiple factors between
the host, the tumour, and the drugs administered. Most studies have emphasised the development or selection
of drug resistant tumour cells. However, repeated drug treatment of the host may lead to changes (e.g. in
pharmacokinetics, host defences, etc.) which can influence the subsequent response of the tumour. In this
study, we present a model to investigate the role of the host in the development of drug resistance. A drug is
administered repeatedly to animals prior to tumour implantation, and tumour response is then evaluated
following treatment with the same drug in pretreated and control animals.
To illustrate the method, cyclophosphamide was administered weekly for 4 weeks to C3H mice before
implantation of the KHT tumour. Tumour growth delay was then compared after one further treatment of
cyclophosphamide in this group of animals to that in control mice which had not received the cyclophospha-
mide pretreatment. Our results indicate that cyclophosphamide produces only a small effect on the host in
this system, but the model is a potentially useful one to investigate the contribution of the host in the
acquisition of drug resistance.
In addition to inherent resistance to drugs, acquired drug
resistance is a common cause of treatment failure in patients,
with tumour regrowth despite chemotherapy which earlier
had caused tumour regression. The major mechanisms lead-
ing to therapeutic failure are thought to involve the gene-
ration of drug resistant tumour cells by mutation, gene
amplification, or epigenetic processes (Ling, 1982; Hill, 1982;
Schimke, 1984). Many anti-cancer drugs are known to
stimulate one or other of these processes, so that the use of
such drugs might increase the frequency of drug-resistant
cells in the tumour. The tumour would then fail to respond
after repeated treatments with the same drug(s), due to
selection of resistant subpopulations (Skipper et al., 1978;
Goldie & Coldman, 1984).
An additional contribution to failure of repeated chemo-
therapy may arise because the patient has been influenced by
prior exposure to the drug so that the tumour appears to be
resistant. This might occur because of (a) altered absorption,
distribution, or excretion of the drug so that less drug
reaches the tumour; (b) increased synthesis or decreased
inactivation of enzymes which degrade the drug; and (c)
decreased tolerance of normal tissues to cytotoxic effects of
the drug so that lower doses have to be given. A survey of
the literature has revealed that the potential role of the host
in the development of drug resistance has not been studied
in any detail. For example, there has been only a limited
number of studies, reported in animals or in humans, of
drug-induced metabolic alterations, or of changes in drug
pharmacokinetics after repeated courses of chemotherapy.
It has ben documented that in mice, the activity of the
liver microsomal enzymes, which are important for the
metabolism of drugs, are stimulated after repeated treat-
ments at therapeutical doses of chlorambucil, methotrexate,
cyclophosphamide, 5-fluorouracil, or hydrocortisone (Donelli
& Garattini, 1971). One report demonstrated decreased host
toxicity in mice during repeated treatment with 5-
fluorouracil (Darnowski et al., 1985). In this study, increased
activity of dihydrouracil dehydrogenase in the liver was
measured, suggesting that increased degradation of 5-
fluorouracil could be induced by chronic treatment with the
drug. Changes in drug metabolism have been reported after
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repeated administration of daunomycin in rats (Nooter et
al., 1984). Decreased intestinal absorption of methotrexate
was also suggested in the rat following repeated oral admi-
nistration of the drug (Sonnevald et al., 1985).
In three clinical studies, the plasma half-life of cyclo-
phosphamide decreased both after repeated low-dose and
high-dose treatments (D'Incalci et al., 1979; Graham et al.,
1983; Sladek et al., 1984). This was probably due to
cyclophosphamide having an inducing effect on enzymes
responsible for its metabolism, leading to an increased rate
of disappearance of its metabolites from plasma. Studies of
the pharmacokinetics of epirubicin in Hodgkin's patients
after repeated courses indicated a slight increase of the total
plasma clearance of the drug in most patients (Vrignaud et
al., 1985). The above studies suggest that the gradual loss of
therapeutic effectiveness observed during prolonged che-
motherapy may in part be a reflection of adaptive pheno-
mena which result in less active drug reaching the target
tumour cells.
In addition to altered pharmacokinetics, interactions
within the tumour-drug-host triad may also be influenced by
the functional status of the host immune system at the time
of drug administration. Since many chemotherapeutic agents
are immunosuppressive, drug treatment may depress various
arms of the immune response so that subsequent drug
treatment appears to have a lesser effect against tumours
which elicit such a response (Santos et al., 1964; Cheema &
Hersh, 1971; Braun & Harris, 1981; Kempf & Mitchell,
1984, 1985). In some experimental systems, host defense
mechanisms have been shown to contribute to the thera-
peutic effects of selected anticancer drugs (Schwartz &
Grindey, 1973; Mantovani et al., 1979).
Studies of tumours in animals which are repeatedly treated
with anti-cancer drugs do not dissect the relative roles of the
host and the tumour in the development of therapeutic
resistance. To investigate the role of the host, we have
monitored tumour response to drug treatment in animals
which had repeated courses of a drug before tumour implan-
tation, as compared to animals which had never seen the
drug before. Cyclophosphamide was used as the experi-
mental drug in these studies because it may induce changes
in its metabolism, is widely administered in chemotherapy,
and because of its known efficacy against the KHT fibro-
sarcoma. The KHT tumour system was chosen because it
has been well characterized, and multiple assays are available
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on it. In addition, we wanted to rule out effects of specific
immune responses in our studies, and this tumour has been
found to be non-immunogenic in its syngeneic host in
other laboratories (Kallman et al., 1967) and ours (R.P. Hill,
unpublished observation).
Materials and methods
Mice and tumours
C3H/HeJ male mice at 7-9 weeks of age, and weighing
between 23-27g were used in all of the experiments. The
experimental tumour was the KHT fibrosarcoma, main-
tained by serial transplantation in syngeneic C3H mice (with
periodic re-establishment from frozen stock). Tumours were
generated by injecting 2 x IO' cells into the left hind leg of
recipient mice, and palpable tumours appeared in -6 days.
In one set of experiments, 1 x 106 cells were injected, and
palpable tumours appeared in 3 days.
Preparation of tumour cell suspensions
Tumour tissue was minced with scissors and incubated with
continuous agitation for 20 min at 37°C in trypsin and
EDTA. Complete culture medium (oc MEM with 10% foetal
bovine serum and 0.1 mgml - kanamycin) was then added
and the suspension was filtered through a fine wire screen.
The cells were then washed once, resuspended in culture
medium, and counted using a haemocytometer. Trypan blue-
excluding tumour cells were scored as viable tumour cells.
Experimental protocol
This is diagrammed in Figure 1. Mice were coded with ear
tags and randomly allocated into 2 groups of at least 14
animals each. One group was given 4 doses of 75 mgkg- I
body weight injection of cyclophosphamide (cyclo) at 1 week
intervals. The other group received isotonic sodium chloride
injection (NaCI). One week after the fourth dose, on day 28,
tumour cells were implanted, and tumour growth monitored.
On day 34 when tumour weight averaged 0.4-0.5 g, each
group was further divided into 2 subgroups of at least 7
animals, one of which received a treatment dose of
75 mgkg-1 body weight cyclo (henceforth designated the
cyclo-cyclo group, and the NaCl-cyclo group), and the other,
which served as controls, received NaCl (the cyclo-NaCl
group, and the NaCl-NaCl group). The endpoint of response
was tumour growth delay. In some experiments, additional
assays (see below) were performed to study possible mecha-
nisms for the observed differences in response in the animal
groups. Instead of cyclo, BCNU (25 mgkg-1 body weight)
or 5FU (100mgkg-1 body weight) were also used for
pretreatment in a few experiments.
In one set of experiments, the dose and schedule of cyclo
pretreatment was changed: mice were given doses of
25mgkg-1 body weight injection of cyclo daily for 5 days,
while the control group received NaCl. Four hours after the
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Figure 1 Experimental protocol.
fifth dose, tumour cells were implanted. Three days later
when tumour weight averaged 0.25 g, each group was further
divided into 2 subgroups, one of each group received a
treatment dose of 75mgkg-1 body weight cyclo, and the
other group received NaCl.
Drugs
Cyclophosphamide (Horner) was dissolved in sterile water;
BCNU (Bristol) was dissolved in 10% ethanol; and 5FU
(Roche) was supplied in solution form. Further dilutions in
0.9% NaCl solution (Squibb) were made as required. Drugs
were given i.p. injection in a volume of 0.01 mlg-1 body
weight. Control animals received injections of 0.9% NaCl
solution.
Measurement of tumour size and growth delay
Tumour size was estimated by passing the tumour-bearing
leg through a graded series of holes drilled in a lucite strip.
The diameter of the smallest hole which could accommodate
the leg without resistance was recorded; tumour weight was
estimated from this diameter using a previously-defined
calibration curve. Tumour size was measured daily or every
other day. Growth delay was the additional time for treated
tumours to grow to 1 g (equivalent to a diameter of
12.5 mm) as compared to untreated tumours. Animals were
coded with eartags to avoid any subjective bias.
Bioassay for cytotoxic metabolites of cyclophosphamide in
blood
To estimate the relative levels of active cyclo metabolites in
the blood of animals in each of the two pretreatment groups,
we used a modification of the method of Tannock (1980)
and Begg and Smith (1984). Survival levels of cultured cells
exposed to serum from animals in the two pretreatment
groups which had received a treatment dose of 75 mgkg-1
cyclo 10 or 30min earlier were compared. Avertin was
injected shortly before blood was obtained from the inferior
vena cava of mice. Because the activity of the metabolites of
cyclo decays very quickly, serum was prepared as rapidly as
possible. Pooled blood from several mice was placed on ice
and centrifuged. The serum was filtered through a 0.22pm
filter once, and 0.8 ml of serum from mice which had
received either NaCl or cyclo injections were added to
3 x 106 exponentially-growing CHO cells in a suspension of
5 ml. The suspensions were agitated gently in a roller wheel
at 37°C for periods of up to 6h. After various times of
exposure to murine serum, cells were centrifuged, resus-
pended in fresh medium, counted, and plated in complete
culture media in triplicate at 3 cell concentrations. The plates
were stained with methylene blue and scored for colonies 10
days later.
In vitro drug treatment and tumour cell survival assay
To test whether pretreatment of animals could influence the
intrinsic response of tumour cells that were subsequently
implanted into them, we assessed the in vitro response of
tumour cells from pre-treated and non-pretreated mice.
Activated cyclo in the form of 4-hydroperoxycyclo-
phosphamide (4HC) was generously supplied by Dr Michael
Colvin (Johns Hopkins). 4HC was dissolved in culture
medium, and various doses were added to tumour cell
suspensions derived from mice which either had the cyclo
pretreatment, or NaCl pretreatment. The cells were incu-
bated with 4HC for 2 h at 37°C with continuous gentle
agitation. They were then washed once and resuspended in
culture medium to be counted. These cells were plated on
plastic culture dishes in complete culture media, and colonies
were counted 12 days later.
Excision assay
Mice were given various doses of cyclo on day 34 and their
tumours excised 24 h after treatment. Cells from at least twoHOST EFFECTS IN DRUG RESISTANCE 135
tumours were pooled to prepare a single-cell suspension for
evaluation of survival at each dose level. Tumour cell
survival was estimated using the clonogenic assay as des-
cribed above.
Table I Tumour regrowth kinetics of the KHT sarcoma after 1
treatment of cyclo, with or without 4 weekly pretreatments of cycloa
Experiment Results
Tumour regrowth
tumour weight
doubling timeb
(days)
Mean tumour
growth delay
+s.e.m.
(days)
Pretreatment of mice with cyclo had no effect on the
subsequent rate of tumour growth. The tumour growth
curves were exponential within the tumour weight range of
0.25g to 1.4g (after which the animals were killed). The
average of 6 independent experiments gave a mean tumour
weight doubling time of 2.7 days for both the NaCl-NaCl
group and the cyclo-NaCl group (range 2.2 to 3.1 days and
2.2 to 3.0 days respectively). In all experiments, mice given
NaCl pretreatment had a larger increase in body weight
(10% more) than cyclo-pretreated mice by day 28.
Table I lists tumour regrowth kinetics of the NaCl-cyclo
and cyclo-cyclo groups in 6 independent experiments, and
representative growth curves are shown in Figure 2. Since
the delay to tumour regrowth appeared to be greater for the
NaCl-pretreated as compared to the cyclo-pretreated groups
in the first two experiments (Figure 2a), studies were carried
out to investigate the possible mechanisms involved:
(a) General status of the host: This was tested by pretreat-
ment of animals with cyclo, followed by treatment with
another drug (5FU) on day 34. The rationale was that
if the four weekly pretreatments of cyclo caused toxi-
city, thereby depressing the host defence mechanisms in
some way, then the tumour growth delay in this
pretreated group of animals would be different from
the non-pretreated group, regardless of the treatment
drug after tumour implantation. Our data indicate that
treatment of animals with 5FU after either cyclo or
NaCl pretreatment did not result in significant differ-
ences in tumour growth delay between the 2 groups
(2.5 days vs. 3.2 days respectively).
HEI NaCl-cyclo
cyclo-cyclo
HE2 NaCl-cyclo
cyclo-cyclo
HE5 NaCl-cyclo
cyclo-cyclo
HE6 NaCl-cyclo
cyclo-cyclo
HE7 NaCl-cyclo
cyclo-cyclo
HE8 NaCl-cyclo
cyclo-cyclo
3.1
3.5
3.8
3.2
2.7
3.0
2.0
2.8
3.6
3.1
2.5
2.7
8.4+0.6
5.3+0.6
5.7+0.5
4.5+0.4
8.7+0.3
8.3+0.4
9.4+0.4
7.6+0.5
7.5+0.5
7.4+0.5
11.0+0.4
9.4+0.5
P=0.0029c
NS
,NS
P=0.031
,NS
P=0.024
aExcept for HE8, in which animals had 1 treatment of cyclo, with
or without 5 daily pretreatments of cyclo. bObtained by linear
regression, each point used for regression being the mean of at least
7 animals. cPaired t test; NS=not significant.
(b) Altered rate of drug metabolism: This was assessed by
use of a bioassay to detect cytotoxic cyclo metabolites
in murine serum in the 2 pretreated groups 10 or
30 min after a treatment dose of cyclo. Figure 3 shows
the result of the bioassay. Murine serum from the
NaCl- or cyclo-pretreated groups which had received
NaCl injections 10 or 30min earlier on day 34 had no
effect on CHO cells (plating efficiency remained -80%
throughout the 6 h exposure period). However, serum
from mice given cyclo 10min earlier was active against
CHO cells, and the level of cell kill was similar in both
the NaCl- and the cyclo-pretreated groups. Some cyto-
toxicity was lost by 30min, but again, there was no
difference between the two groups.
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Figure 2 Growth curves of the KHT sarcoma in mice treated on day 34 when the tumour weighed 0.4g. (a) Data from
experiment HEI; (b) Data from experiment HE5. NaCl-NaCl group (0); NaCl-cyclo group (x); cyclo-NaCl group (0); cyclo-
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Figure 3 Survival of CHO cells treated with serum from mice
which received cyclo 10min (open symbols) or 30min (closed
symbols) earlier. Serum from animals pretreated with cyclo (A,
A); Pretreated with NaCl only (O, 0). Datum points shown are
mean+s.d. This experiment was repeated with qualitatively simi-
lar results.
(c) Altered drug delivery and repair capacity: This was
done by assessing tumour cell survival after treatment
of animals with various doses of cyclo using an
excision assay.
Figure 4 shows the result of the excision assay in
which mice from the NaCl- and cyclo-pretreated
groups were given various doses of cyclo on day 34,
and the tumours excised and plated for survival 24h
later. Survival levels of tumours from both groups were
similar within the range of doses of cyclo studied.
(d) Changes in the tumour cell population: Tumour cell
survival was assessed after in vitro treatment with 4HC
(Figure 5).
Tumour cells from cyclo-pretreated mice seemed to
be slightly more resistant than those from NaCl-
pretreated mice. The shape of the survival curves
suggested that a cell-cycle effect might be involved. This
study was repeated with qualitatively similar results,
although the difference between the two curves was not
significant in the second experiment. Flow cytometric
analysis of cellular DNA content suggested that there
were slightly more S and G2M cells in the NaCI-
pretreated tumours; this effect might reflect decreased
tumour nutrition in animals pretreated with cyclo since
these animals have been found to lose weight.
In summary, the results of these experiments were largely
negative. This was not surprising in retrospect because
assessment of tumour growth delay in these two studies
showed no differences between pretreated and non-pretreated
groups (HE5 and HE7 in Table I and Figure 2b).
In experiment HE8 in which the cyclo-pretreated animals
were given 25mgkg-1 body weight cyclo daily for 5 days
c
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Figure 4 In vitro survival of KHT cells treated with cyclo in
vivo. Tumours from NaCl-cyclo animals (0); Tumours from
cyclo-cyclo animals (A).
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Figure 5 Survival of KHT cells after a 2 h in vitro exposure to
4HC. Tumour cells from NaCI-pretreated animals (x); from
cyclo-pretreated animals (0). Symbols represent mean +1 s.d.
This experiment was repeated with qualitatively similar results.
before tumour implantation, and then the tumour treated 3
days later, there was a small decrease in the subsequent
tumour growth delay of the pretreated animals as compared
to the controls.HOST EFFECTS IN DRUG RESISTANCE 137
Studies with other drugs
The choice of drugs for investigation was limited because the
KHT fibrosarcoma was resistant to most drugs, with the
exception of BCNU and 5FU. Therefore, two experiments
were performed in which animals were treated with either
BCNU, 5FU, or NaCl using the same experimental protocol
described in the above section. It was found that tumour
growth delay was similar between the BCNU-BCNU and
NaCl-BCNU groups (mean of 2 experiments: 5.5 and 5.6
days respectively); and between the 5FU-5FU and NaCl-
5FU groups (2.8 and 2.7 days respectively).
Discussion
We have presented a model which may be used to study the
role of the host in the development of drug resistance in an
animal system. Mice are either given 4 weekly doses of drug
or 5 daily doses before tumour implantation, after which a
further single treatment dose of the same drug is given.
Tumour response in these animals is then compared to that
of animals which have not been pretreated. We have illus-
trated the model by using cyclo to treat the KHT tumour.
In 3 out of 6 experiments, tumour growth delay between
the NaCl-cyclo and the cyclo-cyclo group was significantly
different (P<0.03). In two of the 3 experiments in which no
such difference was observed and in which mechanistic
studies were done, data relating to possibilities of changes in
host toxicity, drug metabolism, and repair capacities of
tumour cell populations were also largely negative.
It was shown that in mice, the same dose of cyclo as used
in the present studies (75mgkg-1) caused a reduction in
white blood cell counts to a nadir at 3 to 4 days, followed by
rapid recovery to control levels by 7 days after treatment
(Tannock, 1980). It is possible therefore that the weekly
pretreatment course was spaced too far apart in time to
markedly cause toxicity of the host by allowing complete
recovery in the white blood cell population. Thus tumour
growth rate was no greater in the cyclo-pretreated mice as
compared to the NaCl-pretreated mice. In addition, animals
treated with 5FU after the 4 weekly doses of cyclo had
similar tumour growth delays to animals which had never
received cyclo.
It had been reported that plasma half-life of cyclo in
patients decreased both during repeated high dose admini-
stration (50 mgkg- I day- I for 4 successive days) and under
continual low dose treatment of cyclo (100mgday-1 for over
1 year) (D'Incalci et al., 1979; Graham et al., 1983). One
possible mechanism is that multiple doses of cyclo have an
inducing effect on enzymes involved in the metabolism of
cyclo, although in another clinical study, no change in cyclo
metabolism was found in patients after 22 days of treatment
with daily doses of 2mgkg-1 (Mouridsen et al., 1976). Our
bioassay failed to detect significant differences of cytotoxic
cyclo metabolite levels in the blood between animals in the
cyclo-cyclo group and the NaCl-cyclo group. Although it
appears that the four weekly doses of cyclo did not markedly
modify the metabolism and pharmacologic activity of cyclo
in the host, the bioassay used in the present studies does not
give a quantitative determination of the various cytotoxic
metabolites of cyclo. In experiment HE8 in which animals
were pretreated daily with 25 mgkg 1 body weight cyclo for
5 days (a combined dose which corresponded to >one-third
of the LD50), the difference between the subsequent tumour
growth delay between the 2 groups of animals was still
small.
In vitro tumour cell survival levels of excised tumours 24 h
after in vivo treatment are determined by an interplay of
multiple factors. If one assumes that the cells obtained by
the trypsinization procedure are representative of all cells in
the intact tumour, difference in the in vitro tumour cell
survival between the 2 pretreatment groups may be caused
by differences in (i) the tumours themselves; (ii) drug meta-
bolism, hence altering the effective dose actually received by
the tumour; (iii) the capacity to repair potentially lethal
damage after treatment; and (iv) a combination of other host
factors. The in vitro tumour cell survival curves of the 2
pretreatment groups showed only small differences in our
experiments.
In conclusion, our results indicate that cyclo does not
reproducibly prolong tumour growth delay in animals pre-
treated with the drug before implantation. Nevertheless, we
have presented a model to investigate the role of the host in
the development of drug resistance. Such a model is useful
for studying the contribution of the host both in increased as
well as decreased therapeutic effectiveness of other drugs. To
obtain optimal therapeutic results, it will be important to
minimize any contribution of the host which might lead to a
decrease in the effectiveness of drugs.
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